| |
| |
|
| Insider
Information: |
Lange Louis G |
| Relationship: |
|
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
582,756 |
|
|
Indirect Shares
|
228,940 |
|
|
| Direct
Value |
$89,185 |
|
|
|
Indirect Value
|
$468,556 |
|
|
| Total
Shares |
811,696 |
|
|
| Total
Value |
$557,741 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
Chairman & CEO, Director |
2009-04-09 |
483,618 |
2009-04-09 |
6,359 |
Premium* |
|
|
Maxygen Inc |
MAXY |
Director |
2012-06-06 |
60,000 |
2009-09-22 |
0 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
Director |
2013-07-01 |
17,814 |
2013-07-01 |
197,703 |
Premium* |
|
|
Cymabay Therapeutics, Inc. |
CBAY |
Director |
2013-10-11 |
1,446 |
|
0 |
Premium* |
|
|
Audentes Therapeutics, Inc. |
BOLD |
Director |
2020-01-15 |
0 |
2020-01-15 |
0 |
Premium* |
|
|
Newamsterdam Pharma Ord Shs |
NAMS |
|
2023-12-29 |
19,878 |
2024-02-13 |
24,878 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
99 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2016-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
466,799 |
|
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2016-07-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
120,501 |
|
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2016-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
15,633 |
14,555 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2016-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
475,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-06-26 |
4 |
AS |
$18.76 |
$296,682 |
D/D |
(15,000) |
460,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-09-25 |
4 |
AS |
$27.85 |
$424,672 |
D/D |
(15,000) |
445,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-09-25 |
4 |
AS |
$27.99 |
$85,055 |
I/I |
(3,000) |
7,558 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-09-29 |
4 |
S |
$28.12 |
$169,588 |
I/I |
(6,000) |
5,558 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-09-29 |
4 |
S |
$28.31 |
$142,315 |
D/D |
(5,000) |
440,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-12-22 |
4 |
AS |
$30.86 |
$92,633 |
I/I |
(3,000) |
4,558 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2017-12-22 |
4 |
AS |
$30.88 |
$463,160 |
D/D |
(15,000) |
425,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-03-26 |
4 |
AS |
$29.00 |
$585,464 |
D/D |
(20,000) |
405,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-03-26 |
4 |
AS |
$28.28 |
$801,473 |
I/I |
(28,000) |
62,343 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-06-25 |
4 |
AS |
$40.74 |
$531,154 |
I/I |
(13,000) |
52,343 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-06-25 |
4 |
AS |
$40.36 |
$808,344 |
D/D |
(20,000) |
385,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-09-24 |
4 |
AS |
$37.25 |
$486,319 |
I/I |
(13,000) |
42,343 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-09-24 |
4 |
AS |
$37.35 |
$747,061 |
D/D |
(20,000) |
365,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-11-15 |
4 |
S |
$22.49 |
$89,960 |
I/I |
(4,000) |
3,555 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-11-15 |
4 |
S |
$22.49 |
$449,800 |
D/D |
(20,000) |
345,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-12-24 |
4 |
AS |
$18.50 |
$222,365 |
I/I |
(12,000) |
32,343 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2018-12-24 |
4 |
AS |
$18.67 |
$373,434 |
D/D |
(20,000) |
325,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2019-03-25 |
4 |
AS |
$35.99 |
$720,015 |
D/D |
(20,000) |
305,799 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2019-03-25 |
4 |
AS |
$35.94 |
$56,058 |
I/I |
(1,558) |
0 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2019-06-24 |
4 |
AS |
$37.89 |
$38,201 |
I/I |
(1,000) |
15,678 |
0 |
- |
|
| BOLD |
Audentes Therapeutics, In... |
Director |
– • – |
2019-06-24 |
4 |
AS |
$37.60 |
$755,413 |
D/D |
(20,000) |
285,799 |
0 |
- |
|
99 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
